Pfizer CFO Dave Denton stepping down in August 2026
Full article text is available in the Catalayer news terminal.
Summary
Pfizer CFO Dave Denton is leaving the company effective August 15 to take a role in consumer goods, with Senior Vice President of Finance Cecile Guegan appointed as interim CFO while Pfizer runs a permanent successor search. Denton joined Pfizer as CFO and guided the company through major acquisitions including Seagen, Biohaven and Metsera.
Market Impact
The CFO transition comes as Pfizer is executing on its post-pandemic reinvention, with Q1 2026 revenue of $14.45 billion reflecting 5% year-over-year growth and 22% operational revenue growth from launched and acquired products. Full-year 2026 guidance remains unchanged at $59.5 billion to $62.5 billion. Guegan has been at Pfizer since 2005 and played a central role in integrating Seagen in 2024. This analysis is informational and avoids any directional trading claims.
Why It Matters
It marks the departure of the CFO who oversaw Pfizer's $43 billion Seagen oncology acquisition and its multi-pronged inorganic growth strategy during a period of post-COVID revenue transition.
Key Points
- Pfizer CFO Dave Denton will depart effective August 15, 2026, moving to a position in consumer goods, with Cecile Guegan serving as interim CFO pending a permanent hire.
- Guegan joined Pfizer in 2005, served as VP of Finance for R&D and the business office from 2020 to 2022, then became SVP of Finance for Pfizer's global biopharmaceutical business in 2022. She played a central role in integrating Seagen in 2024.
- Denton's departure is unrelated to Pfizer's financial or operating results or any accounting or reporting disagreements, per an SEC filing.
- Pfizer reported Q1 2026 revenue of $14.45 billion, up 5% year over year, with 22% operational revenue growth from recently launched and acquired products; full-year guidance remains $59.5 billion to $62.5 billion.
Key Entities
Evidence
Dave Denton, Pfizer's chief financial officer, is departing the pharmaceutical company for a position in consumer goods, with his last day set for Aug. 15, Pfizer announced Thursday.Supports: Supports the departure summary.
Guegan joined Pfizer in 2005 and has held her current role since 2022. She previously served as vice president of finance for research and development and the business office from 2020 to 2022, and played a role in in...Supports: Supports Guegan's background.
When Pfizer reported first-quarter 2026 revenue of $14.45 billion, a 5% year-over-year gain driven by growth in oncology and other recently launched and acquired products, Denton pointed to 22% year-over-year operatio...Supports: Supports the financial performance context.